Webinar
on demand
08
Mar
2023
18
00
CET
Treatment of COVID complications

The outbreak of the Coronavirus disease 2019 (COVID-19) pandemic has caused worldwide problems in the care of cancer patients. In particular, the therapy of cancer patients, both outpatient and inpatient, has been substantially impacted by major restrictions due to the isolation and hygiene measures. Not only the restriction of treatment under pandemic conditions but also a SARS-CoV-2 infection itself poses a risk for cancer patients.

For more information on 'Cancer & Covid: Prevention and Treatment with Monoclonal Antibodies (MoABs)' we invite you to read a report published on the Cancerworld website. Click here to access the full article.

The aim of this session is to spread awareness and knowledge among HCPs on COVID and lung cancer patients, Drugs approved by EMA and the pandemic baricitinib story.

 

The scientific report of this webinar is available on the Cancerworld website. Click here to access the full article.

 

 

Speakers
Discussant
Di Perri Giovanni

University of Turin, Turin, Italy
Expert
Addeo Alfredo

Oncology Division, University Hospital Geneva, Geneve, Switzerland
Expert
Cavaleri Marco

European Medicine Agency, Amsterdam, The Netherlands
Expert
Stebbing Justin

Professor of Biomedical Sciences, ARU, Cambridge, Editor-in-Chief Oncogene and Visiting Prof of Oncology Imperial College London, London, United Kingdom
This material is part of Educational Project:
2023 - Cancer & Covid: Prevention and Treatment including Monoclonal Antibodies (MoABs)